Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Advances study located that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://williamq370iry4.blogdal.com/profile